Centrum Opieki Zdrowotnej Orkan-Med Stec - Michalska Sp. j.
- Address
- lock Available on a paid plan
Digestive System Diseases
The research at Centrum Opieki Zdrowotnej Orkan-Med Stec - Michalska Sp. j. concentrates on Digestive System Diseases, primarily Crohn's Disease and ulcerative colitis. Trials aim to assess the safety and effectiveness of new biologic agents, biosimilars, and combination therapies for patients with moderate to severe disease.
- Long‑term safety and efficacy study of RPC1063 in moderate to severe ulcerative colitis
- Biosimilar AVT16 comparative trial against Entyvio for ulcerative colitis
- Head‑to‑head safety and efficacy comparison of lutikizumab versus adalimumab in ulcerative colitis
- Clinical response evaluation of GS‑1427 in active ulcerative colitis
- Combination therapy of BI 706321 with ustekinumab for Crohn's disease
Located in Ksawerow, Poland, the site collaborates with a small team of investigators to advance treatment options for these chronic intestinal conditions.
Nervous System Diseases
At the same facility, investigators are also exploring therapies for Nervous System Diseases, focusing on migraine. The goal is to evaluate whether a novel preventive medication can lessen attack frequency and improve quality of life for adults who have not responded to existing options.
- Dose‑finding and efficacy assessment of Lu AG09222 for migraine prevention
- Safety and tolerability monitoring of Lu AG09222 in adults with refractory migraine
This work adds a neurological dimension to the centre’s portfolio, complementing its strong emphasis on gastro‑intestinal research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Opieki Zdrowotnej Orkan-Med Stec - Michalska Sp. j.
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, multicenter phase 3 study in patients with moderately to severely active ulcerative colitis (UC) to compare the efficacy, safety and immunogenicity of PB016 and Entyvio® for the induction and maintenance of clinical response and remission. (UCESIVE) | Polpharma Biologics S.A. | Phase III | Not Recruiting | Nov 2023 | Apr 2026 |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Vedolizumab | 2 | Unknown | 2023-11-17 | 2025-08-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.